Fludarabine Powder For Solution For Injection 50Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Fludarabine: Powder for solution for injection (50mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

FLUDARABINE (floo DARE a been) is a chemotherapy drug. It interferes with the growth of cancer cells. It is usually used to treat chronic lymphocytic leukemia (CLL).

In-Depth Information
Select a Medication

Fludarabine 50mg Powder for Injection

NDC: 250210237
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Chronic Lymphocytic Leukemia (CLL)

Sometimes used for but not FDA approved for the following conditions:
Acute Myelogenous Leukemia (AML), Mycosis Fungoides, Non-Hodgkin's Lymphoma (NHL), Prolymphocytic Leukemia (PLL), Stem Cell Transplant Preparation, Cutaneous T-cell Lymphoma (CTCL)

Storage Information
Refrigerate (between 36 and 46 degrees F)
Diluted product must be used within 8 hours
Fludarabine 50mg Powder for Injection

Reported Side Effects for Fludarabine 50mg Powder for Injection

Heart Attack Incidence:
<3.0%*
Severity: SEVERE
Onset: DELAYED
Difficulty Swallowing Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Bleeding Incidence:
<1.0%*
Severity: MODERATE
Onset: EARLY
Mouth Ulcers Incidence:
<9.0%*
Severity: MODERATE
Onset: DELAYED
Sinus Infection Incidence:
<5.0%*
Severity: MILD
Onset: DELAYED
Protein In The Urine Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Lung Inflammation Incidence:
<6.0%*
Severity: MODERATE
Onset: DELAYED
Sore Throat Incidence:
<9.0%*
Severity: MILD
Onset: DELAYED
Osteoporosis Incidence:
<2.0%*
Severity: MODERATE
Onset: DELAYED
Rapid Heart Rate Incidence:
<3.0%*
Severity: MODERATE
Onset: EARLY
Dandruff Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Kidney Failure Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Hypoxia Incidence:
<1.0%*
Severity: MODERATE
Onset: EARLY
Liver Failure Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Anaphylactoid Reactions Incidence:
<1.0%*
Severity: SEVERE
Onset: RAPID
Acute Cerebellar Syndrome Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Tumor Lysis Syndrome (TLS) Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Brain Attack Incidence:
<3.0%*
Severity: SEVERE
Onset: EARLY
Chest Pain Incidence:
<6.0%*
Severity: MODERATE
Onset: EARLY
Joint Pain Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Gallstones Incidence:
<3.0%*
Severity: MODERATE
Onset: DELAYED
Dehydration Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Depression Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Hair Loss Incidence:
<3.0%*
Severity: MILD
Onset: DELAYED
Nose Bleed Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Throat Inflammation Incidence:
<3.0%*
Severity: MODERATE
Onset: DELAYED
Headache Incidence:
<3.0%*
Severity: MILD
Onset: EARLY
Heart Failure Incidence:
<3.0%*
Severity: SEVERE
Onset: DELAYED
Constipation Incidence:
1.0-3.0%*
Severity: MODERATE
Onset: DELAYED
Blood Clot Incidence:
1.0-3.0%*
Severity: SEVERE
Onset: DELAYED
Coughing Up Blood Incidence:
1.0-6.0%*
Severity: MODERATE
Onset: DELAYED
Itching Incidence:
1.0-3.0%*
Severity: MILD
Onset: RAPID
Increased Blood Sugar Incidence:
1.0-6.0%*
Severity: MODERATE
Onset: DELAYED
Irritated Blood Vessels Incidence:
1.0-3.0%*
Severity: MODERATE
Onset: RAPID
Elevated Hepatic Enzymes Incidence:
1.0-3.0%*
Severity: MODERATE
Onset: DELAYED
Diaphoresis Incidence:
1.0-13.0%*
Severity: MILD
Onset: EARLY
Blood In The Urine Incidence:
2.0-3.0%*
Severity: MODERATE
Onset: DELAYED
Deafness Incidence:
2.0-6.0%*
Severity: SEVERE
Onset: DELAYED
Visual Impairment Incidence:
3.0-15.0%*
Severity: SEVERE
Onset: EARLY
Intestinal Bleeding Incidence:
3.0-13.0%*
Severity: SEVERE
Onset: DELAYED
Painful Urination Incidence:
3.0-4.0%*
Severity: MODERATE
Onset: EARLY
Muscle Pain Incidence:
4.0-16.0%*
Severity: MILD
Onset: EARLY
Paresthesias Incidence:
4.0-12.0%*
Severity: MILD
Onset: DELAYED
Feeling Sick Incidence:
6.0-8.0%*
Severity: MILD
Onset: EARLY
Decreased Appetite Incidence:
7.0-34.0%*
Severity: MILD
Onset: DELAYED
Swelling Incidence:
8.0-19.0%*
Severity: MODERATE
Onset: DELAYED
Weakness Incidence:
9.0-65.0%*
Severity: MILD
Onset: EARLY
Cough Incidence:
10.0-44.0%*
Severity: MILD
Onset: DELAYED
Tired Incidence:
10.0-38.0%*
Severity: MILD
Onset: EARLY
Chills Incidence:
11.0-19.0%*
Severity: MILD
Onset: RAPID
Loose Stools Incidence:
13.0-15.0%*
Severity: MILD
Onset: EARLY
Skin Rash Incidence:
15.0%*
Severity: MILD
Onset: EARLY
Shortness Of Breath Incidence:
16.0-22.0%*
Severity: MODERATE
Onset: EARLY
Vomiting Incidence:
31.0-36.0%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
31.0-36.0%*
Severity: MILD
Onset: EARLY
Infection Incidence:
33.0-44.0%*
Severity: MILD
Onset: DELAYED
Low Platelet Count Incidence:
55.0%*
Severity: MODERATE
Onset: DELAYED
Low White Blood Cells Incidence:
59.0%*
Severity: MODERATE
Onset: DELAYED
Anemia Incidence:
60.0%*
Severity: MODERATE
Onset: DELAYED
Fever Incidence:
60.0-69.0%*
Severity: MILD
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

SECOND Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

THIRD Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Fludarabine

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5